» Articles » PMID: 26935133

Direct Comparison of Multiparametric Magnetic Resonance Imaging (MRI) Results with Final Histopathology in Patients with Proven Prostate Cancer in MRI/ultrasonography-fusion Biopsy

Overview
Journal BJU Int
Specialty Urology
Date 2016 Mar 4
PMID 26935133
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To compare multiparametric magnetic resonance imaging (mpMRI) of the prostate and histological findings of both targeted MRI/ultrasonography-fusion prostate biopsy (PBx) and systematic PBx with final histology of the radical prostatectomy (RP) specimen.

Patients And Methods: A total of 105 patients with prostate cancer (PCa) histopathologically proven using a combination of fusion Pbx and systematic PBx, who underwent RP, were investigated. All patients had been examined using mpMRI, applying the European Society of Urogenital Radiology criteria. Histological findings from the RP specimen were compared with those from the PBx. Whole-mount RP specimen and mpMRI results were directly compared by a uro-pathologist and a uro-radiologist in step-section analysis.

Results: In the 105 patients with histopathologically proven PCa by combination of fusion PBx and systematic PBx, the detection rate of PCa was 90% (94/105) in fusion PBx alone and 68% (72/105) in systematic PBx alone (P = 0.001). The combination PBx detected 23 (22%) Gleason score (GS) 6, 69 (66%) GS 7 and 13 (12%) GS ≥8 tumours. Fusion PBx alone detected 25 (26%) GS 6, 57 (61%) GS 7 and 12 (13%) GS ≥8 tumours. Systematic PBx alone detected 17 (24%) GS 6, 49 (68%) GS 7 and 6 (8%) GS ≥8 tumours. Fusion PBx alone would have missed 11 tumours (4% [4/105] of GS 6, 6% [6/105] of GS 7 and 1% [1/105] of GS ≥8 tumours). Systematic PBx alone would have missed 33 tumours (10% [10/105] of GS 6, 20% [21/105] of GS 7 and 2% [2/105] of GS ≥8 tumours). The rates of concordance with regard to GS between the PBx and RP specimen were 63% (n = 65), 54% (n = 56) and 75% (n = 78) in fusion, systematic and combination PBx (fusion and systematic PBx combined), respectively. Upgrading of the GS between PBx and RP specimen occurred in 33% (n = 34), 44% (n = 46) and 18% (n = 19) in fusion, systematic and combination PBx, respectively. γ-correlation for detection of any cancer was 0.76 for combination PBx, 0.68 for fusion PBx alone and 0.23 for systematic PBx alone. In all, 84% (n = 88) of index tumours were identified by mpMRI; 86% (n = 91) of index lesions on the mpMRI were proven in the RP specimen.

Conclusions: Fusion PBx of tumour-suspicious lesions on mpMRI was associated with a higher detection rate of more aggressive PCa and a better tumour prediction in final histopathology than systematic PBx alone; however, combination PBx had the best concordance for the prediction of GS. Furthermore, the additional findings of systematic PBx reflect the multifocality of PCa, therefore, the combination of both biopsy methods would still represent the best approach for the prediction of the final tumour grading in PCa.

Citing Articles

[Predictive effect of the dual-parametric MRI modified maximum diameter of the lesions with PI-RADS 4 and 5 on the clinically significant prostate cancer].

Tian Y, Ruan M, Liu Y, Li D, Wu J, Shen Q Beijing Da Xue Xue Bao Yi Xue Ban. 2024; 56(4):567-574.

PMID: 39041547 PMC: 11284462.


Machine learning prediction of Gleason grade group upgrade between in-bore biopsy and radical prostatectomy pathology.

Ozbozduman K, Loc I, Durmaz S, Atasoy D, Kilic M, Yildirim H Sci Rep. 2024; 14(1):5849.

PMID: 38462645 PMC: 10925603. DOI: 10.1038/s41598-024-56415-5.


Comparative diagnostic accuracy of multiparametric magnetic resonance imaging-ultrasound fusion-guided biopsy systematic biopsy for clinically significant prostate cancer.

Fang J, Zhang L, Xie X, Zhao P, Bao L, Kong F PeerJ. 2023; 11:e16614.

PMID: 38107582 PMC: 10725670. DOI: 10.7717/peerj.16614.


Cognitive fusion-targeted biopsy versus transrectal ultrasonography-guided systematic biopsy: comparison and analysis of the risk of Gleason score upgrading.

Zheng T, Bi K, Tang Y, Zeng Y, Wang J, Yan L Int Urol Nephrol. 2023; 56(3):981-988.

PMID: 37875704 DOI: 10.1007/s11255-023-03848-y.


A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology.

Doblhammer S, Kinger P, Starmuehler M, Muschitz C, Schima W, Susani M World J Urol. 2023; 41(4):1055-1060.

PMID: 36840753 DOI: 10.1007/s00345-023-04339-6.